Latest news with #ANVISA
Business Standard
5 days ago
- Business
- Business Standard
Alde Medi Hosts Groundbreaking 2025 Annual Meeting, Reinforces Commitment to Global Healthcare Innovation
India PR Distribution New Delhi [India], June 23: In a bold step towards redefining the future of healthcare marketing & manufacturing, Alde Medi Impex, a trusted name in the pharmaceutical world, hosted its 25th annual Business Conference 2025. The event brought together healthcare professionals, pharma leaders, and strategic partners under one roof to share insights, foster collaboration, and unveil what the future holds for Alde Medi and the broader healthcare landscape. Far beyond just a milestone, the conference reflected Alde Medi's growing role--not only as a manufacturer but as a driver of innovation, meaningful partnerships, and global trust in healthcare solutions. A Glimpse into the Future: Key Announcements at the Business Conference The energy at the conference was electric, and the announcements made reflected Alde Medi's forward-thinking approach to growth, quality, and innovation. Some of the standout moments included: * A 35% Surge in Domestic Growth Alde Medi recorded a strong 35% growth in India's domestic market driven by focused strategies, deep market understanding, and growing trust among hospitals, institutions, and healthcare providers. * Launching a New-Gen Sterile Injectables Facility Plans for a state-of-the-art sterile injectables facility were unveiled, scheduled for completion by December 2025. Designed to meet the most stringent global standards - EUROPE, SAUDI FDA, and ANVISA, this facility will raise the bar for quality, precision, and compliance in Indian pharma manufacturing. * ALDEVIT Gold Climbs to the Top ALDEVIT Gold, the company's flagship multivitamin, was recognised as India's 47th top brand among over 1,600 multivitamin products (as per IMS Health data). A proud achievement that reflects growing demand and credibility in the wellness segment. * Exports Skyrocket by 80% Alde's exports soared by 80% in 2024, marking a major leap in its global footprint. Now officially a Government Recognized Export House, Alde Medi has over 100 product registrations across 20+ countries and active exports in 35+ global markets with team size of more than 100 professionals contributing at different part of the world . The next big leap: entering Brazil and Mexico with plans to file 200+ new dossiers in 2025 in various countries. * Somediza Lifesciences: Generic Division Launched With the launch of Somediza Lifesciences, Alde enters the generic space backed by a clear goal to become one of India's most quality-focused generic pharma companies. The division aims to make trusted, affordable medicines accessible to all. * Critical Care Division Doubles Its Impact 2024 saw 100%+ growth in Alde's Critical Care Division, which now supplies to top hospitals like Metro Group and Venkateshwara Hospital in Delhi. The next phase of growth will focus on expanding into MAX Healthcare, Yashoda, and Kailash Hospitals, ensuring critical treatments are within reach when they're needed the most. Alde Medi: More Than a Manufacturer--A Platform for Ideas, Impact, and Innovation The conference wasn't just about business, it was a space for meaningful conversations and forward-looking ideas. Topics explored included: * The evolving regulatory landscape across countries * How AI and automation are reshaping pharmaceutical production * Best practices in clean, sustainable manufacturing * Opportunities for strategic partnerships across borders * Innovative product portfolio for next 2 years defined * Market penetration strategies were discussed It was a powerful reminder that healthcare is no longer local, it's global. And Alde Medi is ready to lead from the front. About Alde Medi Impex: A Legacy of Innovation and Trust Founded in 1997 , Alde Medi Impex has grown from a humble beginning into a globally respected name in pharmaceutical manufacturing. Backed by WHO, GLP, and ISO certifications, the company specialises in injectable dosage forms including Liquid Injections, Dry Powder Injections, and Lyophilized Injections delivering life-saving sterile solutions to both Indian and global markets. But Alde Medi is more than just a manufacturing powerhouse. It has earned its reputation as a reliable healthcare partner, with a focus on quality, compliance, and scalable operations. In addition to pharmaceuticals, the group is also building diversified platforms that cater to modern needs, across travel, shopping, and everyday conveniences. Our Ventures: * Alde Expression - A PIC/s & EU-GMP certified manufacturing facility * Alde Bazaar - A comprehensive e-commerce platform * Truvel - A smart travel booking platform Leadership Speaks: Building a Future That Cares "With each vial, every solution we make carries a promise--our promise to protect lives." -- Chairman, Alde Group The leadership at Alde Medi made it clear: while the company is scaling rapidly, it remains deeply rooted in its values, compassion, quality, and purpose. A people-first culture, where learning, innovation, and accountability go hand-in-hand, continues to drive the company's momentum forward. From One Room to the World: A Timeline of Growth * 1997- : Alde Medi was born with a five-member team and a big dream * 1997-2012: Expanded steadily across Uttar Pradesh and North India * 2012- 2018: Manas Rastogi ( in Biotechnology , MBA in Marketing from UK ) joined as marketing director . Exponential growth in domestic market - team size , new product launches , diversification to cardiology / neurology / metabolic products . These 6 years made alde medi one of the renowned name in north indian pharmaceutical industry. * 2019-2020: Manas promoted as CEO, Array of expansion and diversification began, transformation of alde medi impex limited to Alde group. Group companies : Globezza biotech ( nutraceutical division ) , somediza lifesciences ( generic division ) , Alde export ( international division ) , Alde medi ( marketing division ) , Alde real estate , Truvel services ( travel arm ) , Alde Bazaar ( E commerce ) * 2020-2025: Ambitious roadmap targeting 300% growth, global market expansion, and breakthrough innovations Looking Ahead The Business Conference 2025 was more than a corporate event, it was a celebration of shared purpose, progress, and possibility. With a clear focus on healthcare accessibility, sustainable innovation, and global partnerships, Alde Medi is building something bigger than just a business.
Business Standard
17-06-2025
- Business
- Business Standard
Hikal clears ANVISA GMP audit at Bengaluru API unit
Hikal said that it has successfully cleared the Good Manufacturing Practices (GMP) inspection conducted by the Brazilian Health Regulatory Agency (ANVISA) at its API manufacturing unit in Jigani, Bengaluru, Karnataka. The audit, which covered multiple active pharmaceutical ingredients (APIs), was conducted from 14 April to 18 April 2025. The successful completion of the inspection reinforces Hikals compliance with international quality standards and strengthens its position in regulated markets like Brazil. Hikal is engaged in the business of pharmaceuticals, crop protection, and specialty chemicals. The companys consolidated net profit rallied 48.08% to Rs 50.20 crore on 7.44% rise in revenue from operations to Rs 552.40 crore in Q4 FY25 over Q4 FY24. Shares of Hikal rose 0.29% to Rs 377.10 on the BSE.
Business Standard
17-06-2025
- Business
- Business Standard
Stock Alert: Zee Entertainment, Hikal, NTPC, Biocon, Hyundai Motor India
Secutries in F&O Ban: Aditya Birla Fashion & Retail (ABFRL), Birla Soft, Central Depository Services (CDSL), Chambal Fertilisers & Chemicals, HUDCO, Indian Renewable Energy Development Agency (IREDA), Manapurram Finance, RBL Bank and Titagrah Rail Systems shares are banned from F&O trading on 17 June 2025. Stocks to Watch: Zee Entertainments board approved the proposal to raise Rs 2,237 crore from promoter entities via issuing 16.95 crore warrants at issue price of Rs 132 per share. The warrants are proposed to be allotted to Altillis Technologies and Sunbright Mauritius Investments. Biocons board approved the issuance of qualified institutional placement (QIP) of Rs 4,500 crore at floor price of Rs 340.20 per equity share. Hikal has successfully passed the Brazilian Health Regulatory Agencys (ANVISA) GMP audit for its manufacturing unit located at Jigani in Bengaluru, Karnataka. The inspection, carried out by ANVISA, Brazil GMP (good manufacturing practices), was for multiple APIs which occurred from April 14th to April 18th, 2025. Hyundai Motor India has successfully commenced production of Passenger Vehicle Engines at its manufacturing facility Talegaon Plant located at Plot No. A-16, MIDC, Talegaon Industrial Area, Phase-II Expansion, Pune, Maharashtra, with effect from 16 June 2025. NTPCs board has scheduled a meeting on 21 June 2025, to consider the issuance of secured/ unsecured, redeemable, taxable/tax-free, cumulative/non-cumulative, non-convertible debentures (bonds/NCDs) aggregating upto Rs 18,000 crore, subject to approval of shareholders.
Business Standard
17-06-2025
- Business
- Business Standard
Indices drift lower in early trade; breadth positive
The key equity benchmarks traded with minor losses in early trade, driven by rising geopolitical tensions between Israel and Iran. Geopolitical developments are expected to continue influencing the market direction, as investors closely track crude oil prices, the G7 summit, Bank of Japans policy decision and the outcome of the upcoming U.S. Federal Reserve meeting later this week. The Nifty slipped below the 24,900 level. Pharma, auto and consumer durables shares declined while realty, media and PSU Bank shares advanced. At 09:25 IST, the barometer index, the S&P BSE Sensex declined 165.48 points or 0.20% to 81,630.67. The Nifty 50 index fell 66.55 points or 0.26% to 24,880.30. In the broader market, the S&P BSE Mid-Cap index rose 0.02% and the S&P BSE Small-Cap index fell 0.18%. The market breadth was positive. On the BSE, 1,436 shares rose and 1,348 shares fell. A total of 174 shares were unchanged. Foreign portfolio investors (FPIs) sold shares worth 2,539.42 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 5,780.96 crore in the Indian equity market on 16 June 2025, provisional data showed. Stocks in Spotlight: Zee Entertainment Enterprises advanced 1.52% after the companys board approved the proposal to raise Rs 2,237 crore from promoter entities via issuing 16.95 crore warrants at issue price of Rs 132 per share. The warrants are proposed to be allotted to Altillis Technologies and Sunbright Mauritius Investments. Biocon shed 0.92%. The companys board approved the issuance of qualified institutional placement (QIP) of Rs 4,500 crore at floor price of Rs 340.20 per equity share. Hikal rose 0.51%. The company has successfully passed the Brazilian Health Regulatory Agencys (ANVISA) GMP audit for its manufacturing unit located at Jigani in Bengaluru, Karnataka. The inspection, carried out by ANVISA, Brazil GMP (good manufacturing practices), was for multiple APIs which occurred from April 14th to April 18th, 2025. Numbers to Track: The yield on India's 10-year benchmark federal paper fell 0.22% to 6.257 from the previous close of 6.270. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 85.8900 compared with its close of 86.0450 during the previous trading session. MCX Gold futures for 5 August 2025 settlement fell 0.29% to Rs 98,850. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.01% to 98.17. The United States 10-year bond yield shed 0.49% to 4.430. Global Markets: US Dow Jones futures were down 133 points, signaling a weak start for Wall Street. Asian shares were a mixed bag on Tuesday as investors kept a close watch on the simmering Israel-Iran tensions. All eyes are now on the Bank of Japan, which is set to announce its policy decision later in the day. Expectations are that the BOJ will hold interest rates steady at 0.5%, opting for caution amid a murky global trade outlook. Back in the US, Wall Street closed in the green overnight. Hopes for a de-escalation in the Middle East boosted sentiment, with the Dow Jones climbing 0.75%, the S&P 500 gaining 0.94%, and the Nasdaq leading the rally with a 1.52% jump. On the corporate front, Roku shares popped after the company unveiled a new exclusive partnership with Amazon Ads. The deal is set to create the largest authenticated Connected TV (CTV) footprint in the US, a major win in the growing streaming ad market. Meanwhile, the US Federal Reserve begins its two-day meeting today. While interest rates are widely expected to remain unchanged at around 4.5%, the spotlight will be on any hints of a pivot to rate cuts, especially as inflation cools and growth shows signs of fatigue. Across the border, G7 leaders are gathering in Canada this week. The mood might be tense, with US President Donald Trumps tariffs on allied imports casting a shadow. Canadian PM Mark Carney has promised a push for peace and stability but hinted at potential retaliatory tariffs if Washington doesnt ease up on its steel and aluminum duties.
&w=3840&q=100)
Business Standard
29-05-2025
- Business
- Business Standard
Here's why Natco Pharma share price is buzzing in trade on Thursday, May 29
Natco Pharma share price: Pharmaceutical company Natco Pharma share price rose as much as 6.66 per cent to hit an intraday high of ₹919.90 per share. However, by 12:01 PM, Natco Pharma share price was off day's high, and was trading 2.48 per cent higher at ₹883.80 per share. In comparison, BSE Sensex was trading flat with a negative bias at 81,287.30 level. Why did Natco Pharma share price rise in trade today? Natco Pharma share price rose on the back of a healthy March quarter of financial year 2025 (Q4FY25) results. The pharma company's consolidated profit after tax (PAT) rose to ₹406 crore in the March quarter of FY25, from ₹386.3 crore in the March quarter of FY24. At the operating level, earnings before interest, tax, depreciation and amortisation (Ebitda) soared to ₹614.4 crore in the March quarter of FY25, from ₹539.3 crore in the March quarter of FY24. However, Ebitda margin squeezed to 47.7 per cent in Q4FY25, from 48.6 per cent a year ago. About Natco Pharma Natco Pharma is a Hyderabad-based pharmaceutical company engaged in the development, manufacturing, and distribution of both generic and branded drugs. The company also operates in the specialty pharmaceutical and crop protection segments. Known for its strong focus on research and development, the company is a science-driven organisation with a leadership position in oncology, particularly in targeted therapies within the Indian market. In the United States, it concentrates on launching complex and limited-competition molecules. The company operates nine manufacturing facilities and two research and development (R&D) centres across India. Its production sites are accredited by major global regulatory agencies, including the US FDA, Brazil's ANVISA, Health Canada, and the World Health Organization (WHO), among others. Through its extensive compliance and quality framework, Natco Pharma serves over 50 international markets, reinforcing its global footprint in the pharmaceutical sector.
